Navigation Links
Luminex Corporation First Quarter Earnings Release Scheduled for April 29, 2013
Date:4/8/2013

>® real-time polymerase chain reaction (PCR) and multiplex PCR-based technologies, that deliver cost-effective and rapid results to clinicians and researchers. Luminex's technology is commercially available worldwide and in use in leading clinical laboratories as well as major pharmaceutical, diagnostic, biotechnology and life-science companies. The Company is meeting the needs of customers in markets as diverse as clinical diagnostics, pharmaceutical drug discovery, biomedical research including genomic and proteomic research, personalized medicine, bio-defense research and food safety. For further information on Luminex Corporation and the latest advances in multiplexing using award winning technology, please visit http://www.luminexcorp.com.

Statements made in this release that express Luminex Corporation's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. The words "believe," "expect," "intend," "estimate," "anticipate," "will," "could," "should" and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company's actual results or performance could differ materially from those anticipated or projected in such forward-looking statements. Factors that could cause Luminex's actual results or performance to differ materially include risks and uncertainties relating to, among others, market demand and acceptance of Luminex's products, the Company's dependence on strategic partners for development, commercialization and distribution of products, concentration of the Company's revenue in a limited number of strategic partners, fluctuations in quarterly results due to a lengthy and unpredictable sales cycle and bulk purchases of consumables, Luminex's ability to scale manufacturing operations and manage ope
'/>"/>

SOURCE Luminex Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Luminex Corporation Reports First Quarter 2012 Results
2. Luminex Corporation Announces Agreement to Acquire GenturaDx
3. Luminex Corporation Second Quarter Earnings Release Scheduled for July 30, 2012
4. Luminex Corporation Reports Second Quarter 2012 Results
5. Luminex Corporation and University Hospital of Wales Collaborate During Olympic Games
6. Luminex Corporation Awarded $11 Million Contract by Defense Threat Reduction Agency (DTRA)
7. Luminex Corporation Recognized as Best Technology Company in Austin
8. Luminex Corporation Hosts 10th Annual Planet xMAP Symposium in Monaco
9. Luminex Corporation To Present At Upcoming Investment Conferences In September
10. Luminex Corporation Reports Third Quarter 2012 Results
11. Luminex Corporation To Present At Leerink Swann Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , 11. Juli 2014  Dilon ... für die molekulare Bildgebung, einschließlich molekularer ... die CE-Zulassung für sein Navigator ® ... Dilon das Produkt jetzt europaweit vertreiben. ... Großteil der europäischen Länder ausgedehnt und ...
(Date:7/10/2014)... 2014  RESMED INC. (NYSE: RMD ) today ... year ended June 30, 2014 results on Thursday, July 31, ... press release with ResMed,s results will be issued after 1:00 ... webcast to discuss operating results and future outlook. ... US Pacific Time and the live webcast of the call ...
(Date:7/10/2014)... July 10, 2014   Ventana Medical Systems, Inc. ... it has entered into an agreement with Merck KGaA, ... EMD Serono in the United States ... with Merck KGaA,s biopharmaceutical division on the development and ... target using Ventana,s proprietary diagnostic assays. In alignment with ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... June 4 Mylan Inc. (Nasdaq: MYL ) ... approval from the U.S. Food and Drug Administration (FDA) for its ... and 800 mg, the generic version of Pfizer,s Neurontin® Tablets for ... will be distributed by Mylan Pharmaceuticals Inc. , ...
... June 4 Syndax Pharmaceuticals, Inc., a ... Phase 2, open-label ENCORE 303 trial in post-menopausal women ... were progressing on aromatase inhibitor (AI) therapy. Safety and ... a poster at the American Society of Clinical Oncology ...
Cached Medicine Technology:Mylan Receives Approval for Generic Version of Neurontin® Tablets 2Syndax Pharmaceuticals' Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer 2Syndax Pharmaceuticals' Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer 3Syndax Pharmaceuticals' Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer 4
(Date:7/11/2014)... FL (PRWEB) July 11, 2014 American ... on RFD-TV, next Tuesday, July 15, 2014, at 8:30 ... Sunbelt's line of proprietary products, which are designed and ... crops. Audiences will learn how these products help the ... environment in which it is grown. , The show ...
(Date:7/11/2014)... Alliance Labs announced that they will be featured ... Jr, airing later this year 2014, via Discovery Channel. ... Innovations will explore DocuSol® Kids, a mini-enema containing a ... base designed to give adolescents general constipation relief. Viewers ... hyperosmotic laxative by drawing water into the bowel from ...
(Date:7/11/2014)... July 11, 2014 College athletes experiencing ... week of injury, but developed recurrent instability in 63% ... American Orthopaedic Society for Sports Medicine’s ( AOSSM ) ... physicians in providing the most optimal treatment plans for ... an anterior shoulder instability event, and found that 33 ...
(Date:7/11/2014)... 11, 2014 Anterior Cruciate Ligament (ACL) ... the type of material used to create a new ... game, say researchers presenting their work today at the ... Medicine ( AOSSM ). , “Our study ... (tissue harvested from a donor) fail more frequently than ...
(Date:7/11/2014)... repaired knee Anterior Cruciate Ligament (ACL) happens all too ... the American Orthopaedic Society for Sports Medicine,s (AOSSM) Annual ... risk factors may minimize the chance of a future ... few risk factors such as, age, activity level and ... of re-injury," said lead author, Christopher C. Kaeding, MD ...
Breaking Medicine News(10 mins):Health News:New Episode of American Farmer Featuring Sunbelt, UniSouth Genetics, and Michigan Milk Producers Association Airing on RFD-TV 2Health News:Alliance Labs & DocuSol® to be Featured in Upcoming Episode of Innovations 2Health News:Intercollegiate Contact Athletes with Shoulder Instability Return to In-Season Sports, Study Shows 2Health News:ACL Reconstructions May Last Longer With Autografts 2
... antibodies in migrant birds in five Siberian regions, a spokesman ... ,"Out of over 4,000 samples taken in the area this ... genetic material of the A-H5 virus and antibodies in their ... the presence of antibodies meant that either the birds had ...
... assess the effectiveness and tolerability of subdermal implantable contraceptives ... that they were all good at preventing pregnancy. ... be any more or less effective than the others ... effect with all the implants was changes in bleeding ...
... atrial fibrillation (AF) have irregular heart beats and have a ... (atria) of their hearts. These clots can then travel to ... ,One way of reducing the risk of this occurring is ... clots. Two commonly used options are anticoagulants that inhibit the ...
... smoking to secure peoples' rights to the highest standards of ... implementing a comprehensive anti-tobacco law to reduce the spread of ... Ali bin Shukur, Under-secretary of the Ministry of Health, was ... bill on smoking is being deliberated at the UAE Ministerial ...
... found in turmeric may help beat Alzheimer's, which is ... ,Researchers isolated the compound 'bisdemethoxycurcumin' found in turmeric, which ... the body against infections and diseases. ... patients and treat the incurable and fatal brain condition, ...
... six-month phase of a calorie-restriction study conducted at the ... Aging (USDA HNRCA) at Tufts University suggest that,accepting food ... important component of weight management. ,Supplemental results ... Restricting Intake of Energy (CALERIE) trial provide new insights ...
Cached Medicine News:Health News:Anticoagulants is Better for Atrial Fibrillation 2Health News:Food Cravings are Linked to Weight Managenemt 2Health News:Food Cravings are Linked to Weight Managenemt 3
... Addressing the key clinical and economic issues ... System is designed to maximize tension control ... The system combines efficient instrumentation with a ... Grip system is indicated for general orthopaedic ...
... In 1985, the worlds first ... by Howmedica Osteonics as a means ... wire for trochanteric reattachment procedures. Today, ... papers demonstrating clinical successes, the Dall-Miles™ ...
The Assistant Free Self-Retaining Hip Surgery Retractor System is used for hip arthroplasty and hip fracture surgery....
... have become the accepted standard for,excellence and ... AML Total Hip System was the first ... meet the needs for biological fixation in ... 15 years of documented clinical performance, the ...
Medicine Products: